234 related articles for article (PubMed ID: 17335299)
1. Agalsidase Beta: a review of its use in the management of Fabry disease.
Keating GM; Simpson D
Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on agalsidase beta in Fabry disease.
Keating GM; Simpson D
BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
[TBL] [Abstract][Full Text] [Related]
3. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
Beck M
Expert Opin Investig Drugs; 2002 Jun; 11(6):851-8. PubMed ID: 12036428
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
6. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
7. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
[TBL] [Abstract][Full Text] [Related]
9. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM; Tylki-Szymańska A; Hilz MJ
Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
12. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.
Beck M
Expert Opin Biol Ther; 2009 Feb; 9(2):255-61. PubMed ID: 19236256
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
Desnick RJ
Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.
Eto Y; Ohashi T; Utsunomiya Y; Fujiwara M; Mizuno A; Inui K; Sakai N; Kitagawa T; Suzuki Y; Mochizuki S; Kawakami M; Hosoya T; Owada M; Sakuraba H; Saito H
J Inherit Metab Dis; 2005; 28(4):575-83. PubMed ID: 15902561
[TBL] [Abstract][Full Text] [Related]
17. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
Ohashi T; Sakuma M; Kitagawa T; Suzuki K; Ishige N; Eto Y
Mol Genet Metab; 2007 Nov; 92(3):271-3. PubMed ID: 17689998
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
19. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
